Stock Market News3 months Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal Zacks
SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.
XSYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.
X